Dapagliflozin Medical Uses

Dapagliflozin is adumbrated for the administration of diabetes mellitus type 2, and functions to advance glycemic ascendancy in adults if accumulated with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to abundant glycosuria (glucose elimination in the urine), which can advance to weight accident and tiredness. Dapagliflozin was accustomed by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the analysis of diabetic ketoacidosis.

In July 2011 a U.S. Food and Biologic Administration (FDA) endocrinologic and metabolic drugs advising board recommended adjoin approval until added extracts were available.

The FDA accustomed dapagliflozin on January 8, 2014 for glycemic control, forth with diet and exercise, in adults with type 2 diabetes.

In 2012, the Board for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a absolute assessment on the drug. It is now marketed in a amount of European countries.

The FDA accustomed the aggregate artefact dapagliflozin and metformin hydrochloride extended-release, called Xigduo XR, in October 2014.

In Feb 2017 the FDA accustomed a once-daily aggregate of dapagliflozin 10 mg and saxagliptin 5 mg, as Qtern.